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Abstract
A tumor promoting role of macrophages has been described for a transgenic murine breast cancer model. In this model
tumor-associated macrophages (TAMs) represent a major component of the leukocytic infiltrate and are associated with
tumor progression. Shigella flexneri is a bacterial pathogen known to specificly induce apotosis in macrophages. To evaluate
whether Shigella-induced removal of macrophages may be sufficient for achieving tumor regression we have developed an
attenuated strain of S. flexneri (M90TDaroA) and infected tumor bearing mice. Two mouse models were employed,
xenotransplantation of a murine breast cancer cell line and spontanous breast cancer development in MMTV-HER2
transgenic mice. Quantitative analysis of bacterial tumor targeting demonstrated that attenuated, invasive Shigella flexneri
primarily infected TAMs after systemic administration. A single i.v. injection of invasive M90TDaroA resulted in caspase-1
dependent apoptosis of TAMs followed by a 74% reduction in tumors of transgenic MMTV-HER-2 mice 7 days post infection.
TAM depletion was sustained and associated with complete tumor regression. These data support TAMs as useful targets
for antitumor therapy and highlight attenuated bacterial pathogens as potential tools.
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Introduction
Ever since the American surgeon Coley described streptococcal
infection as a potential cure of cancer [1], other bacteria have been
explored and were shown to infiltrate, replicate and accumulate in
tumors [2,3]. For some extracellular bacteria, such as genetically
modified obligate anaerobe Clostridium novyi, an anti-tumor effect
was observed [4]. Other extracellular bacteria such as Escherichia
coli accumulated in tumor tissue, induced some inflammatory
responses, but failed to confer protection [5]. Facultative
intracellular bacteria such as Salmonella have also been assessed
for tumor therapy and their intratumoral accumulation was
studied using different technologies, albeit beyond cellular
resolution [6,7,8,9]. In most syngenic experimental models the
therapeutic effect was moderate, whereas in xenograft models a
more pronounced effect was described [7,9,10,11,12]. It was
speculated that induction of an inflammatory response was
mediating the anti-tumor effect.
In contrast to extracellular bacteria, intracellular bacteria can
deliver DNA into eukaryotic cells [13]. Therefore, intracellular
bacteria could be employed to deliver toxins or prodrug
converting enzymes directly into tumor cells. Yet, no quantita-
tive information on the distribution of intracellular bacteria in
d i f f e r e n ts t r o m a lv e r s u st u m o rc e l l si sa v a i l a b l ee v e nt h o u g h
such data are key to the design of effective therapeutic regimens
[14].
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stroma cells [15]. In many tumors, tumor-associated macrophages
(TAMs) represent a major component of the leukocytic infiltrate
[16]. High macrophage numbers have been reported in breast,
ovarian, prostate, pancreatic and cervical cancers and are
associated with poor prognosis [16,17]. Some authors have
characterized TAMs as macrophages expressing protumoral
functions, including promotion of tumor angiogenesis, metastasis,
matrix remodelling and suppression of adaptive immunity
[16,18,19,20]. Similar results have recently been obtained for
tumor associated neutrophils [21].
Removal of macrophages or neutrophils reduced the rate of
tumor progression in murine tumor models [21,22]. Evidence
suggests that TAMs are tumor-educated macrophages that appear
to have defective production of reactive oxygen and nitrogen
intermediates and are impaired in phagocytic activity [16]. For
normal macrophages it is known that they are a primary target of
virulent Shigella flexneri [23]. Shigella flexneri infection triggers
caspase-1 activation leading to apotosis and processing of IL-1
and IL-18 [23].
To analyse the distribution of shigellae after i.v. application in
tumor models with high numbers of macrophages (Supporting
Information S1: Fig. S1), we quantified the numbers of bacteria in
the extracellular space or within tumor cells, distinguishing
between the macrophages and non-macrophages. Here we show
that TAMs were the primary target of invasive shigellae in a 4T1
tumor xenograft - and a transgenic MMTV-HER2 - breast cancer
model. Metabolically attenuated, invasive Shigella flexneri were
almost exclusively found intracellularly, whereas a non-invasive S.
flexneri mutant predominantly located extracellularly. Invasive
shigellae, but not non-invasive shigellae, were able to activate
caspase-1 and induce apoptosis in TAMs in both breast cancer
models. Shigellae induced apoptosis caused a substantial depletion
of TAMs, which was correlated with a pronounced and long-
lasting therapeutic effect in the 4T1 breast cancer model. Finally,
apoptosis induction by Shigella was confirmed ex vivo with freshly
isolated human TAMs.
Taken together the data suggests that invasive bacteria capable
of inducing apoptosis in macrophages might represent a novel and
promising therapeutic approach for a macrophage-targeted tumor
therapy.
Materials and Methods
Ethics Statement
All animals experiments were carried out in accordance with
protocols approved by the Regierung von Unterfranken, Ger-
many.
Media, Chemicals and Other Reagents
Bacteria were grown on trypticase soy broth, trypticase soy
agar (Becton Dickinson), LB broth, LB Agar (Sigma-Aldrich) or
BHI (Becton Dickinson). Ampicillin-, chloramphenicol-, and
kanamycin-resistant transformants were selected on agar
containing the respective antibiotic at 100, 25, and 30 mg/ml.
L-arabinose (Sigma-Aldrich) was used at 1 mM for gene
expression induction. TSA containing 100 mg/l of Congo red
dye was used to select Cr+ clones of S. flexneri.[ 2 4 ]
Oligonucleotides (Eurofins MWG Operon), Enzymes (Fermen-
tas) and Taq polymerase (Biotherm, Genecraft) were used
according to manufacturers’ instructions. Qiagen products were
used to isolate plasmid DNA, gel-purify fragments, or purify
PCR products.
Bacterial Strains, Growth Conditions
The S. flexneri serotype 5a strains used in this study are the wt
M90T (streptomycin (Sm) resistant] and its noninvasive variant
BS176 (lacking the virulence plasmid pWR100) [25,26]. Strains
containing pKD46 and pCP20 were incubated at 30uC unless
otherwise noted.
Generation of Shigella aroA-Mutants
Linear DNA containing antibiotic resistance genes were pre-
pared from the plasmids pKD3 according to the method
described by Datsenko and Wanner [27]. Briefly, a PCR-product
was generated by using primers AroA_up (GGGGTTTTTA-
TTTCTGTTGTAGAGAGTTGAGTTCATGGAATCGTGT-
AGGCTGGAGCTGCTTC) and AroA_down (GGCCGTGCA-
TTTGGGATCAAGAATCGTCACTGGTGTATCTGCATA-
TGAATATCCTCCTTA) with 36 nucleotide extensions that are
homologous to the AroA-gene. As a template, the pKD3 plasmid,
which carries a chloramphenicol resistance gene flanked with FRT
sites, was used. The PCR-product was transformed into electro-
competent Shigella flexneri BS176, carrying the recombinase
encoding plasmid pKD46. In positive clones, the resistance
cassette was eliminated using the flipase encoding helper plasmid
pCP20 and finally the temperature sensitive helper plasmid was
eliminated.
The resulting strain Shigella flexneri BS176DaroA (termed
BS176DaroA) was transformed with the virulence plasmid
pWR100 isolated from S. flexneri M90T and pCP20 as helper
plasmid. After selection and elimination of the helper plasmid the
mutant S. flexneri BS176DaroA pWR100 was obtained. The mutant
carries the main feature of the virulent strain M90T and therefore
was termed M90TDaroA (M90TD).
Determination of CFU and Number of Infected Cells
CFUs were determined by plating serial dilutions in PBS
containing 0.1% Triton-X (Roth) and plating on LB agar plates
for shigellae strains. Colonies were counted after incubation
overnight. For determination of the number of infected cells,
serial dilutions were made in PBS, mixed with 5ml of 50uC heated
SeaPlaque Agarose (Biozym Scientific) and dropped on LB agar
plates. The number of bacterial colonies was counted after
overnight incubation. Every colony marks an infected eukaryotic
cell.
HeLa Cell Invasion Assays and Survival Assay
Invasion and survival in HeLa (American Type Culture
Collection, ATCC; CCL-2) cells was assessed using a modified
gentamicin protection assay as previously described [28]. Briefly,
six-well plates were seeded with 2 ml of HeLa cell suspension
adjusted to 2610
5 cells/ml and incubated overnight to reach 90%
confluency. Log-phase (OD600: 0.6–0.8) cultures of bacteria were
added at an estimated MOI of 100 and plates were incubated at
37uC for 1 h. Subsequently plates were washed three times with
PBS and then incubated with DMEM containing gentamicin
(100 mg/ml) for 1 h at 37uCi n5 %C O 2. HeLa cells were lysed in
a 0.1% Triton X-100 solution for 10 min at different time points
and CFU was determined.
Cell to Cell Spreading Assay
To determine cell to cell spread with a growth attenuated strain
a new assay was employed. HeLa cells (7610
5) grown in 6-well
tissue culture plates were infected at a MOI of 500 for 1 h and
then washed twice with PBS. Infected cells were irradiated at 20
Gray. Subsequently, a monolayer of uninfected HeLa cells grown
Cancer Therapy by Shigella
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HeLa cells in a ratio of 70:1 for 2 h, 8 h and 12 h. After 1 h
incubation with 100 mg/ml gentamicin, the concentration of
gentamicin was reduced to 10 mg/ml. The number of infected cells
was determined as described above.
Analysis of Caspase-1, Caspase-3, IL-1b, IL-18 and PARP
Processing by Western Blot
Up to 1610
6 cells were washed twice with PBS and lysed in
120 ml of 2x Laemmli buffer at 100uC. 10–30 ml of lysates were
separated by SDS-PAGE and transferred onto nitrocellulose
membranes (Schleicher & Schuell). After 1 h blocking in 5%
skimmed milk (Applichem), the membranes were incubated with
the primary antibodies (anti-caspase-1/ICE, Sigma); anti-cleaved
caspase-3 antibody (NEB), anti-IL1b antibody (BioVision), anti-
IL18 antibody (BioVision) anti-cleaved PARP antibody (BD
Pharmingen), anti-GAPDH antibody (Chemicon international)
or anti-b-actin antibody (Sigma-Aldrich) diluted in 5% skimmed
milk overnight at 4uC. After washing, the blot was incubated with
peroxidase-conjugated secondary antibody (GE Healthcare).
Detection was performed using the ECL kit (Amersham
Biosciences) and exposure on X-ray film (Kodak).
Mice and Tumor Inoculation
Six- to eight-week-old female mice were injected subcutaneously
with either 1610
4 4T1 cytokeratine positive murine epithelial
mammary cancer cells (ATCC, CRL-2539), 1610
6 B78-D14 [29]
melanoma cells or 1610
6 P815-PSA [30] mastocytoma cells each
resuspended in 50 ml PBS. Injections were done on both sides of
the shaven abdomen.
Balb/c, C57/BL6, DBA-2 mice were obtained from Harlan
Winkelmann GmbH, Germany. Transgenic MMTV-HER2/new
FVB mice were obtained from Jackson Laboratory [31]. All
animals were housed at the MSZ animal care facility and
experiments were carried out in accordance with protocols
approved by the Regierung von Unterfranken, Germany.
Histological and Immunohistochemical Analysis of
Tumors
Tumors grown to approximately 1.5 cm in diameter were
excised aseptically. The tumors were formalin-fixed, sectioned,
and stained with hematoxylin and eosin (Sigma-Aldrich).
To identify macrophages at the tumor site, tissues were fixed in
4% buffered paraformaldehyde for one day, paraffin-embedded,
and processed for sectioning. Sections were immunostained using
the pan-macrophage anti-F4/80 rat monoclonal antibody (Acris
Antibodies) and specific reactivity was detected using a peroxidase-
based detection kit (Vector Laboratories). Inflammation by
immune cells was detected using an anti-CD45 antibody (BD
Pharmingen) and the peroxidase-based detection kit. For identi-
fication of epithelial cells an anti-Cytokeratin antibody (DAKO)
and a biotinylated anti-IgG antibody (DAKO) were used.
Assessment of In Vivo Targeting and Apoptosis Induction
Shigella were harvested in mid-logarithmic phase, washed three
times in PBS and diluted in PBS prior to injection. CFU was
determined before by plating serial dilutions of infection aliquots. 4T1
tumor-bearing Balb/c mice 14 days post cell implantation or approx.
6 months old female MMTV-HER2 mice bearing spontaneous
mammary carcinomas were injected with 1610
6 CFU of bacteria
into the tail vein. Bacterial titers were confirmed by plating serial
dilutions. Mice were sacrificed at different time points and organs
were removed. Organs were digested in 0.001% DNAse (Sigma-
Aldrich) and 2 mg/ml dispase solution (Invitrogen) for 30 min at
37uC and homogenized with 70 mma n d4 0mm cell strainers. Cell
numbers of every cell fraction were counted using a Bu ¨rkercounting
chamber. For separation of cellular populations, parts of the cells
were labelled with the pan-macrophage anti-F4/80 (anti-mouse IgG,
Acris Antibodies; anti-human IgG, Santa Cruz) antibody for 20
minutesat4uC. Subsequently, labelled cellswere stained with an anti-
IgG antibody conjugated to magnetic beads (Miltenyi-Biotec) for 10
minutes at 4uC. Cell separation was performed with the MACS Kit
(Mitenyi-Biotec) according to the manufacturers protocol. Subse-
quently, every cell fraction was counted using a Bu ¨rker counting
chamber. The CFU, the number of infected cells, caspase-1
processing and apoptosis induction was determined for every cell
fraction. To determine the fraction of intra- and extracellular
bacteria, CFU of total cells was determined in the presence or
absence of 300 mg/ml gentamicin. For absolute values, detection
limit is 10 for CFU determination and 1 for infected cells. For values
relative to the cell numbers, detection limit is calculated for each
experiment using the limit for absolute values divided by the highest
number of cell counts for tumor cells, the macrophage or non-
macrophage fraction. Detection limits for spleen cells (not shown) are
usually 10 fold lower due to higher cell numbers.
FACS Analysis
T h er e l a t i v ea m o u n to fm a c r o p h a g e si nt u m o rt i s s u e sw a s
determined by FACS. After blocking the Fcc receptor (anti-CD16/
32, BD Pharmingen), cells were stained with FITC-anti-mouse
CD11b (Miltenyi-Biotec;10minutesat4uC),phycoerythrin(PE)-anti-
mouse Gr-1 (Miltenyi-Biotec; 10 minutes at 4uC) or PE-anti-mouse
F4/80 (Acris Antibodies; 30 minutes at 4uC). FITC or PE coupled
IgG2B antibody (RD Systems,) were used as isotype control. Total cell
numbers were assessed in a FSC/SSC live gate. Flow cytometric
analysis was performed on a FACSCalibur (BD Immunocytometry
Systems) according to the manufacturer’s instructions.
Efficacy Studies
Therapeutic efficacy of Shigella infection on tumor growth was
explored in 28 six- to eight-week-old female Balb/c mice bearing
4T1 tumors. Tumor growth was determined every two days with a
caliper. At day 14 post cell implantation, mean tumor volume had
reached 170 mm
3 and 24 mice were randomized into three
groups. A total amount of 1610
6 M90TDaroA, BS176DaroA or
100 ml PBS were injected into the lateral tail vein of the tumor-
bearing mice. Tumor size was monitored every second day.
Tumor volume was calculated with the formula V=p/6*a*b
2
(a.b). 31 days after tumor cell implantation the nave and the
BS76DaroA group (tumor volume of approx. 4000 mm
3) and two
M90TDaroA mice (macroscopic comparison of tumors, data not
shown) were sacrificed. On day 62 post tumor cell implantation
M90TDaroA-infected mice were sacrified to determine CFU in
tumor, liver, spleen and for FACS and histological analysis.
Statistical Analysis
Statistical analysis was performed using Graph Pad Prism 4
(GraphPad Software). Data were compared and analyzed for
statistical significance by using a two-tailed Student’s t-test whereas
p,0.05 was considered as significant.
Results
Generation and In Vitro Characterization of Attenuated
Shigella Strains
For infection, S. flexneri serotype 5a strains M90T and BS176
were used. BS176 is a variant of M90T lacking the virulence
Cancer Therapy by Shigella
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studies was constructed, by chromosomal deletion of the aroA-gene
locus. Isogenic virulent and avirulent strains were generated by
attenuating Shigella flexneri strain BS176 to yield BS176DaroA
followed by transfer of the virulence plasmid pWR100 [25]. The
resulting mutant was called M90TDaroA.
The strains were characterized with respect to extracellular and
intracellular growth, adhesion, invasion and cell-to-cell spread in
vitro (Fig. 1). The attenuated mutants had a reduced maximal
growth rate in LB medium compared to the parental strains with
functional aroA-genes (Fig. 1A). With respect to association and
invasion, S. flexneri M90TDaroA was indistinguishable from the
M90T strain (Fig. 1B). Consistent with the behaviour of other aroA
deleted mutants the intracellular replication was reduced (Fig. 1C).
To determine the cell-to-cell spread, a spreading assay was
applied, which is independent of intracellular replication (see
material and methods section). S. flexneri M90TDaroA was actively
spreading as a 6- or 17-fold increase of infected cells was seen at 8
vs 12 hours post coincubation (Fig. 1D). In contrast the isogenic
control BS176DaroA was only marginally active (Fig. 1D).
The capacity of S. flexneri M90TDaroA to induce both caspase-1
cleavage (Fig. 1E) and apoptosis (Fig. 1F) was confirmed in
J774A.1 macrophages by western blot analysis (Supporting
Information S1: Fig. S2). Apoptosis induction by S. flexneri
M90TDaroA was caspase-1 dependent, as the caspase-1 specific
inhibitor YVAD-CHO fully blocked caspase-1 and PARP
processing (Fig. 1E).
Infection of TAMs by Shigella In Vivo
In the next set of experiments, 1610
6 invasive S. flexneri
M90TDaroA or non-invasive BS176DaroA derivative were applied
i.v. to 4T1 xenografted Balb/c or tumor-bearing transgenic
MMTV-HER2 mice. After tumor removal, single cell suspensions
were prepared and treated with or without gentamicin to
determine the ratio of extra and intracellular bacteria. Parts of
the tumor cell suspension were separated by MACS into a TAM
fraction and TAM-depleted fraction using an F4/80 antibody
(Supporting Information S1: Fig. S3,4,5). Supporting Information
S1: Fig. S3,4 also depicts the phenotypic characterization of the
TAMs. 83% of CD11b positive cells were F4/80 positive
(Supporting Information S1: Fig. S3). The F4/80 positive
population is DC-M negative, MHC class II low and Gr-1
negative (Supporting Information S1: Fig. S4). The number of
infected cells was determined by plating in L-Top agar.
Similar to observations with other bacterial strains, both
invasive and non-invasive Shigella accumulated and persisted in
the tumor after i.v. infection, whereas they were rapidly eliminated
in the spleen (Fig. 2A, C). However, both strains showed marked
differences with respect to their intra-tumoral distribution. In the
4T1 tumor model, gentamicin treatment revealed that 6 h after
infection the invasive S. flexneri M90TDaroA almost exclusively
located intracellularly, whereas only 2% of the non-invasive
derivative were located intracellularly (Fig. 2A). Seven days after
application invasive Shigella reached total CFU levels of up to
6610
6 per tumor. Unexpectedly, the invasive strain was
predominantly located in TAMs (.10 fold enrichment, Fig. 2C)
even though M90TDaroA readily infected epithelial 4T1 cells in
culture (Supporting Information S1: Fig. S11). In case of the non-
invasive BS176DaroA, only a small amount of bacteria were found
that were restricted to macrophages 6 h p.i. (Fig. 2A), in line with
previous reports [5]. Seven days after infection, non-invasive
shigellae remained restricted to TAMs and were at the limit of
detection (Fig. 2A). In contrast the ratio of invasive bacteria in
TAMs vs non-TAMs was decreased at seven days p.i. presumably
due to cell to cell spreading as observed in cell culture (Fig. 1E,F).
The predominant localization in TAMs was not due to higher
CFU counts per cell compared to non-macrophages, as the
infectious center assay led to the same results (Fig. 2B, D). The
selective targeting of invasive shigellae to TAMs was also observed
in tumor bearing MMTV-HER2 transgenic mice (Fig. 2E, F).
Taken together, non-invasive BS176DaroA shigellae were mainly
found extracellularly despite the presence of large numbers of
macrophages in two different breast cancer models, whereas
invasive M90TDaroA shigellae almost exclusively targeted TAMs.
Apoptosis Induction in TAMs
To examine whether the apotosis induction observed in the
established macrophage cell line J774A.1 in culture also occurred
in TAMs in vivo, tumor bearing mice were infected. After
infection with invasive M90TdaroA shigellae, caspase-1 activation
(Fig. 3A) was detectable in total cells and macrophage fractions of
tumors taken 6 hours after infection. At seven days p.i. caspase-1
activation was exclusively seen in the macrophage fraction.
Caspase-1 activation at either timepoint was invariantly associated
with IL-18 and IL-1b processing (Fig. 3B,C) in addition to
processing of the effector caspase-3 and PARP cleavage
(Fig. 3A,D), a hallmark of apoptosis. In contrast the non-invasive
BS176DaroA did not induce apoptosis. Apoptosis induction was
only observed in cellular fractions, where shigellae were located
intracellularly and that contained TAMs. Similar data were
obtained for transgenic MMTV-HER2 mice (Fig. 3E). In both
mouse models TUNEL staining in tumor tissue confirmed
caspase-3 processing and PARP cleavage data (Supporting
Information S1: Fig. S8).
Next we investigated whether apoptosis induction in vivo was
associated with depletion of macrophages. Figure 4 shows that
M90TDaroA, but not the avirulent shigellae reduced the relative
content of TAMs in tumors from xenografted Balb/c mice by at
least 50% seven days p.i. (Fig. 4A). In transgenic mice a 74%
reduction was achieved by M90TDaroA but not control shigellae
infection at the seven day timepoint (Fig. 4B). This result cannot be
explained by differences in tumor sizes between animals
(Supporting Information S1: Fig. S9) and therefore strongly
suggests that infection with invasive bacteria induced the depletion
of TAMs. In addition, the reduction of macrophages is not
observed in spleens of infected animals suggesting that the
reduction is confined to tumor tissues (data not shown).
Histological examination of non-infected (Fig. 4C left panels),
BS176DaroA (Fig. 4C, middle panels) and M90TDaroA (Fig. 4C
right panels) infected mice by anti-F4/80 staining confirmed the
substantial reduction of macrophages. Additionally the IHC
experiments revealed massive infiltration of inflammatory cells
(anti-CD45 staining) in 4T1-tumors upon infection with invasive
but not non-invasive Shigella (Fig. 4C). Furthermore, cytokeratin
staining of tumors derived from M90TDaroA-infected mice, which
identifies pockets of 4T1 tumor cells showed reduced content of
cytokeratin positive cells. This result indicates that the depletion of
macrophages is associated with a reduction of tumor cells as
previously observed by other approaches targeting macrophages
[19,33,34]. In the non-infected and BS176DaroA-infected tissue
normal tumor structure was observed.
Tumor Regression by Depletion of TAMs
To investigate whether this substantial reduction in macrophage
numbers and marked inflammation induced by S. flexneri
M90TDaroA is associated with a therapeutic effect, bacteria were
applied to tumor-bearing Balb/c mice and tumor growth was
Cancer Therapy by Shigella
PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9572Figure 1. In vitro characterization of aroA mutants. (A) Determination of extracellular growth rate in LB medium. (B) Invasion assay (gentamicin
protection assay). CFUs are shown relative to the wt M90T. (C) Intracellular replication rate in HeLa cells. (D) Cell to cell spread in HeLa cells assessed
by L-Top agar assay. Western blot analysis for caspase-1 activation (caspase-1*) (E) and apoptosis induction was performed in J774A.1 Macrophages
(PARP cleavage - cPARP) (F). Bars represent means +/- SD of three different experiments, *** P,0.001. BS176: Shigella flexneri BS176; BS176D: Shigella
flexneri BS176DaroA; M90T: Shigella flexneri M90T; M90TD: Shigella flexneri M90TDaroA.
doi:10.1371/journal.pone.0009572.g001
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PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9572Figure 2. Shigella flexneri M90TDaroA predominantly targeted TAMs in vivo. Determination of CFU/cell number (A, C, E) and infected cells/
cell number (B, D, F) of separated tumor cells and spleen cells 6 h and 7d after i.v. infection with 1610
6 bacteria of tumor-bearing 4T1 (A–D) and
transgenic MMTV-HER2/neu mice (E, F). Corresponding raw data of CFU and infected cell counts are shown in Supporting Information S1: Fig. S6 and
Supporting Information S1: Fig. S7. + indicates gentamicin treatment. Dashed lines indicate detection limits. All results shown are mean 6 SD of
values from three mice per experiment; ** P,0.01, *** P,0.001. BS176D: Shigella flexneri BS176DaroA; M90TD: Shigella flexneri M90TD aroA
doi:10.1371/journal.pone.0009572.g002
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PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9572assessed (Fig. 5A). Infection with S. flexneri BS176DaroA resulted in
a small, albeit significant reduction of tumor growth in comparison
to the control animals. In contrast, a single i.v. infection with S.
flexneri M90TDaroA resulted in complete removal of tumor tissue
(Fig. 5). 48 days p.i. the tumor showed very low macrophage
(,4%) numbers and bacteria were not detectable (Fig. 5A).
Histological examinations of the tumor tissue 68 days after
xenografting showed persistent reduction of macrophage numbers
Figure 3. Infection of tumor-bearing mice with Shigella flexneri M90TDaroA, but not S. flexneri BS176DaroA induced consistent
caspase-1 processing and apoptosis in TAMs in vivo. Western Blot analysis for caspase-1 (A, E), IL-1b (C), IL-18 (B), caspase-3 (D) processing and
PARP cleavage (A,E) in Balb/c (A–D) and transgenic MMTV-HER2 (E) mice. BS176D: Shigella flexneri BS176DaroA; M90TD: Shigella flexneri M90TDaroA
doi:10.1371/journal.pone.0009572.g003
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PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9572(anti-F4/80 staining) and complete depletion of 4T1 tumor cells
(anti-cytokeratin staining) (Fig. 5B).
Discussion
In this work we have demonstrated that invasive S. flexneri
preferentially target TAMs after i.v. infection in two different
breast cancer models. The growth-attenuated virulent mutant
M90TDaroA, but not the non-invasive mutant BS176DaroA, was
exclusively located intracellularly at all time points examined.
Mutant M90TDaroA, but not BS176DaroA, induced caspase-1
processing and apoptosis in TAMs leading to a long-lasting
reduction of TAMs. The reduction of TAMs was accompanied by
a complete tumor regression in a 4T1 breast cancer model and
removal of transformed cells in the residual stroma. In contrast to
bacterial tumor therapies that use extracellular bacteria, targeting
TAMs with invasive shigellae was effective despite relatively low
numbers of bacteria within the tumor. Finally, for a different
gynaecological cancer type of human origin, human ovarian
carcinoma, we could show ex vivo that infection of TAMs from
ascites with S. flexneri M90TDaroA induced caspase-1 activation
and PARP cleavage (Supporting Information S1: Fig. S10).
Experimental tumor therapy by infection with extracellular
bacteria has a long history [3]. Recent observations with E.coli
strains suggested that these bacteria were able to induce tumor-
targeted inflammatory responses but were ineffective in killing
tumor cells [5]. The non-invasive strain BS176DaroA showed a
similar behavior, including a marginal, albeit significant, thera-
peutic efficacy. Bacterial tumor therapy is commonly thought to be
based on the induction of an inflammatory response at the site of
the tumor as a result of the accumulation of extracellular bacteria
at this immunologically privileged site [4,11,35]. Whereas these
bacteria remain extracellular at all times S. flexneri M90TDaroA
actively invades cells. This data confirm previous reports which
have described phagocytosis defects in TAMs [16,19].
Figure 4. Infection with Shigella flexneri M90TDaroA results in a decrease in TAMs number. 7d after IV infection of tumor bearing Balb/c (A)
and MMTV-HER2 FVB mice (B) tumors were analysed for F4/80 positive cells by FACS to determine the relative amount of TAMs. Bars represent means
+/2 SD of four tumors analyzed per group, ** P,0.01, *** P,0.001. (C) Histology of tumor tissue from non-infected, BS176D- or M90TD- infected
mice. In each case left panels represent antibody controls. Scale bars represent 50 mm. BS176D: Shigella flexneri BS176DaroA; M90TD: Shigella flexneri
M90TDaroA; CK: Cytokeratin.
doi:10.1371/journal.pone.0009572.g004
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PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e9572Figure 5. M90TD, but not BS176D, completely blocked tumor growth after i.v. infection of 4T1 tumor-bearing mice. (A) 14 days after
tumor cell inoculation 1610
6 bacteria were applied i.v. to 8 mice per group. Non-infected and BS176D infected mice were sacrificed 31 days after
tumor cell inoculation. At day 62, M90TD mice were killed and CFU and macrophage numbers were determined. ** P,0.01, *** P,0.001. (B)
Histology of tumor tissue from M90TD-infected mice. Left panels represent antibody controls. Scale bars represent 50 mm. BS176D; Shigella flexneri
BS176DaroA; M90TD; Shigella flexneri M90TDaroA;CK: Cytokeratin.
doi:10.1371/journal.pone.0009572.g005
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associated with complete tumor regression [36]. The simplest
interpretation of these data would be that TAMs are required to
support tumor growth. However as we observed a massive
infiltration of inflammatory cells simultaneous with bacterial
infection and TAM depletion inflammation might also contribute
to tumor regression. The extracellular BS176DaroA mutant did not
induce caspase-1 processing and thus did neither induce IL-1b and
IL-18 activation nor deplete TAMs. Therefore it is likely that for
the induction of the inflammatory response by M90TDaroA
targeting of macrophages is also a necessary factor. However the
low dose bacteria found under these conditions makes it difficult to
come up with a firm conclusion in this respect. As neutrophils have
been described to be potential mediators of inflammation induced
tumor regression [21] it may be interesting in the future to
determine whether M90TDaroA can induce neutrophil infiltration
in the presence or absence of TAMs.
Targeting TAMs as a strategy for bacterial tumor therapy may
have the advantage that a stable cell population is attacked as
opposed to the phenotypically unstable tumor cell population, that
may quickly give rise to resistant cells. On the other hand
macrophages found in tumors may potentially stimulate or inhibit
tumor growth. It will therefore be important in the future to
develop markers that differentiate between TAM populations and
allow identification of tumors where TAM removal may be
beneficial [37,38]. Although at first sight Shigella would seem to be
an unlikely candidate as a therapeutic agent based on its
pathogenicity, the fact that attenuation was readily achieved and
that a small number of bacteria at the tumor site was sufficient to
induce a dramatic anti-tumor effect suggests that further
investigation is warranted. At least in our experiments we did
not observe signs of overt toxicity, albeit mice cannot be
considered as a suitable model to assess toxicity of shigellae.
In summary, we suggest that targeting TAMs using attenuated
S. flexneri is a promising option for future tumor therapy. Further
studies are required with respect to the safety of the S. flexneri
mutant and the efficacy of tumor targeting in humans.
Furthermore, other intracellular bacteria like Salmonella enterica or
Listeria monocytogenes might be suitable for a macrophage targeted
bacterial tumor therapy.
Supporting Information
Supporting Information S1
Found at: doi:10.1371/journal.pone.0009572.s001 (15.15 MB
DOC)
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